PD-0848 Stereotactic body radiotherapy for poor surgical candidates with primary renal cell carcinoma

2021 ◽  
Vol 161 ◽  
pp. S682-S683
Author(s):  
Y.Y. Jo
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Stereotactic Body Radiotherapy ◽  
Renal Cell ◽  
Primary Renal Cell Carcinoma

Stereotactic Body Radiotherapy for Large Primary Renal Cell Carcinoma

2017 ◽  
Vol 15 (5) ◽  
pp. e851-e854 ◽  
Author(s):  
Orit Kaidar-Person ◽  
Alex Price ◽  
Eric Schreiber ◽  
Timothy M. Zagar ◽  
Ronald C. Chen
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Stereotactic Body Radiotherapy ◽  
Renal Cell ◽  
Primary Renal Cell Carcinoma ◽  
Large Primary

scholarly journals Stereotactic Body Radiotherapy for Frail Patients with Primary Renal Cell Carcinoma: Preliminary Results after 4 Years of Experience

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3129
Author(s):  
Laure Grelier ◽  
Michael Baboudjian ◽  
Bastien Gondran-Tellier ◽  
Anne-Laure Couderc ◽  
Robin McManus ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Stereotactic Body Radiotherapy ◽  
Renal Cell ◽  
Dose Fractionation ◽  
Free Survival ◽  
Primary Renal Cell Carcinoma ◽  
Frail Patients ◽  
Fractionation Schedule ◽  
Tertiary Center

Introduction: The aim of this study was to report the oncological outcomes and toxicity of stereotactic body radiotherapy (SBRT) to treat primary renal cell carcinoma (RCC) in frail patients unfit for surgery or standard alternative ablative therapies. Methods: We retrospectively enrolled 23 patients who had SBRT for primary, biopsy-proven RCC at our tertiary center between October 2016 and March 2020. Treatment-related toxicities were defined using CTCAE, version 4.0. The primary outcome was local control which was defined using the Response Evaluation Criteria in Solid Tumors. Results: The median age, Charlson score and tumor size were 81 (IQR 79–85) years, 7 (IQR 5–8) and 40 (IQR 28–48) mm, respectively. The most used dose fractionation schedule was 35 Gy (78.3%) in five or seven fractions. The median duration of follow-up for all living patients was 22 (IQR 10–39) months. Local recurrence-free survival, event-free survival, cancer-specific survival and overall survival were 96 (22/23), 74 (18/23), 96 (22/23) and 83% (19/23), respectively. There were no grade 3–4 side effects. No patients required dialysis during the study period. No treatment-related deaths or late complications were reported. Conclusion: SBRT appears to be a promising alternative to surgery or ablative therapy to treat primary RCC in frail patients.

Stereotactic body radiotherapy for primary renal cell carcinoma and adrenal metastases

2017 ◽  
Vol 6 (S2) ◽  
pp. S17-S17 ◽  
Author(s):  
Gargi Kothari ◽  
Alexander V. Louie ◽  
David Pryor ◽  
Ian Vela ◽  
Simon S. Lo ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Stereotactic Body Radiotherapy ◽  
Renal Cell ◽  
Adrenal Metastases ◽  
Primary Renal Cell Carcinoma

502: Effect of Sunitinib in Patients with Unresectable Primary Renal Cell Carcinoma

2007 ◽  
Vol 177 (4S) ◽  
pp. 167-168 ◽  
Author(s):  
Anil Thomas ◽  
Brian R. Lane ◽  
Brian I. Rini ◽  
Steven C. Campbell
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Primary Renal Cell Carcinoma

Synchronous and Metachronous Contralateral Adrenal Metastases from Primary Renal Cell Carcinoma

1997 ◽  
Vol 58 (1) ◽  
pp. 58-60 ◽  
Author(s):  
Avi Stein ◽  
Yoel Mecz ◽  
Yanina Sova ◽  
Miriam Lurie ◽  
Aharon Lurie
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Adrenal Metastases ◽  
Primary Renal Cell Carcinoma

scholarly journals Mediastinal Metastasis 10 Years after Primary Renal Cell Carcinoma<br/>—A Report of a Case and a Review

2016 ◽  
Vol 06 (08) ◽  
pp. 127-137
Author(s):  
Mustafa Rifat ◽  
Usama Nihad Rifat ◽  
Khalid Al-Safi ◽  
Hassan Z. Annab
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Primary Renal Cell Carcinoma ◽  
Mediastinal Metastasis
Sign in / Sign up

Export Citation Format

Share Document